Aisa Pharma is focused on developing a novel treatment for the pressing medical needs of patients with Systemic Sclerosis (or Scleroderma) who demonstrate Raynaud’s phenomenon. Preliminary clinical data is encouraging and implies treatment effects of our drug on both Raynaud’s and aspects of the underlying disease and associated symptoms
About AISA-021
AISA-021 is being developed to treat Systemic Sclerosis and the Raynaud’s Phenomenon that affects 95% of patients with the disease.
Our Team
We have decades of experience in pharmaceutical product development.
Contact Us
Keep in touch! Submit a question or subscribe to our mailing list.